Celyad Oncology SA
F:1C0

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
F:1C0
Watchlist
Price: 0.1375 EUR -0.36% Market Closed
Market Cap: 1.6m EUR

Net Margin

-3 470.4%
Current
Improving
by 15 578%
vs 3-y average of -19 048.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-3 470.4%
=
Net Income
€-6.5m
/
Revenue
€186k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-3 470.4%
=
Net Income
€-6.5m
/
Revenue
€186k

Peer Comparison

Country Company Market Cap Net
Margin
BE
Celyad Oncology SA
XBRU:CYAD
7.1m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
162.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.5B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 99% of companies in Belgium
Percentile
1st
Based on 487 companies
1st percentile
-3 470.4%
Low
-13 700% — 1.5%
Typical Range
1.5% — 14.7%
High
14.7% — 97 950%
Distribution Statistics
Belgium
Min -13 700%
30th Percentile 1.5%
Median 7.4%
70th Percentile 14.7%
Max 97 950%

Celyad Oncology SA
Glance View

Market Cap
1.6m EUR
Industry
Biotechnology

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

1C0 Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-3 470.4%
=
Net Income
€-6.5m
/
Revenue
€186k
What is Celyad Oncology SA's current Net Margin?

The current Net Margin for Celyad Oncology SA is -3 470.4%, which is above its 3-year median of -19 048.4%.

How has Net Margin changed over time?

Over the last 2 years, Celyad Oncology SA’s Net Margin has increased from -69 588.6% to -3 470.4%. During this period, it reached a low of -69 588.6% on Jun 30, 2023 and a high of -3 131.2% on Dec 31, 2024.

Back to Top